A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays

International Journal of Cancer

Volumn 124, Issue 9, 2009, Pages 2124-2134

  Charpin, Colette ^a   Secq, Véronique ^a   Giusiano, Sophie ^a   Carpentier, Séverine ^a   Andrac, Lucile ^a   Lavaut, Marie Noëlle ^a   Allasia, Claude ^a   Bonnier, Pascal ^b   Garcia, Stéphane ^a  

^a HÔPITAL NORD   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Breast cancer; Molecular signature; Prognosis; Quantitative immunocytochemistry

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN; CD44V6 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MOESIN; PROGESTERONE RECEPTOR; PROTEIN CK14; PROTEIN KINASE FYN; PROTEIN P21; PROTEIN P27; PROTEIN SHARP2; SCATTER FACTOR RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; COMPUTER PROGRAM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENSITOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TISSUE MICROARRAY; ADENOCARCINOMA; BREAST TUMOR; CANCER INVASION; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; IMMUNOPRECIPITATION; METABOLISM; METASTASIS; PATHOLOGY; RISK FACTOR; ROC CURVE; SURVIVAL RATE;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; ROC CURVE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 63449121643     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24177     Document Type: Article

References (51)

1. Perou CM, Sorlie T, Eisen MB, Van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-752
2. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
3. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423
5. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004;64:8558-8565
6. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, Bild A, Iversen ES, Huang AT, Nevins JR, West M. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci USA 2004;101:8431-8436 (Pubitemid 38736592)
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826
8. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-3743
9. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-1192
10. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-1533 (Pubitemid 35332911)
11. Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004;10:6143-6151 (Pubitemid 39287520)
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez- Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, et al. Immunohistochemical and clinical characterization of the basal- like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374
13. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 2002;161:1223-1233
14. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767-779
15. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006;25:2273-2284
16. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271 (Pubitemid 43117611)
17. Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007;121:1779-1785
18. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu- Lehtinen P, Malmstrom P, Wilking N, Bergh J, Isola J. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006;12:4185-4191
19. Da Silva L, Clarke C, Lakhani SR. Demystifying basal-like breast carcinomas. J Clin Pathol 2007;60:1328-1332 (Pubitemid 350247248)
20. Reis-Filho JS, Tutt AN. Triple negative tumors: a critical review. Histopathology 2008;52:108-118 (Pubitemid 350265179)
21. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007;50:434-438 (Pubitemid 46328193)
22. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and cMet and with proteomic basal-like phenotype. Hum Pathol 2007;38:830-841 (Pubitemid 46726507)
23. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez Penuela J, Udvarhely N, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-268
24. Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P, Lavaut MN, Allasia C. CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up. Am J Clin Pathol 1997;107:534-541 (Pubitemid 27183985)
25. Charpin C, Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, Lavaut MN, Allasia C, Bonnier P. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 2004;10:5815-5819 (Pubitemid 39180960)
26. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Choux R, Lavaut MN, Allasia C. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol 1998;109:431-438 (Pubitemid 28151031)
27. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN, Allasia C. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays. J Pathol 1998;184:401-407 (Pubitemid 28179899)
28. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN, Allasia C. Bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up. J Clin Oncol 1998;16:2025-2031 (Pubitemid 28265036)
29. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N, Piana L. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994;86:1539-1545 (Pubitemid 24330219)
30. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut MN, Allasia C. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997;28:289-296 (Pubitemid 27106080)
31. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of cMet and of the transducers PI3K, FAK and. JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 2007;31:49-58.
32. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005;365:488-492 (Pubitemid 40215731)
33. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-835
34. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, Ponta H. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 2007;18:76-83. (Pubitemid 46066712)
35. Niggli V, Rossy J. Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol 2008;40:344-349
36. Tang P, Cao C, Xu M, Zhang L. Cytoskeletal protein radixin activates integrin alpha(M)beta(2) by binding to its cytoplasmic tail. FEBS Lett 2007;581:1103-1108
37. Chen SY, Chen HC. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 2006;26:5155-5167 (Pubitemid 43955827)
38. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, et al. Caveolin 1 is overexpressed and amplified in a subset of basal- like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13:90-101.
39. Liedtke C, Kersting C, Burger H, Kiesel L, Wulfing P. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007;5:110. (Pubitemid 350167996)
40. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L, Lavaut MN, Allasia C, Carpentier-Meunier S, Bonnier P, Charpin-Taranger C. cMet overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer 2007;96:329-335 (Pubitemid 46160639)
41. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C. Prediction of metastasis risk (11 year follow-up) using VEGF-R1. VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n5905). Br J Cancer 2004;90:1216-1221
42. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004;35:176-183 (Pubitemid 38240899)
43. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-739 (Pubitemid 41099705)
44. Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C, Charpin C. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005;26:977-984
45. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803 (Pubitemid 46657376)
46. Kurt M, Harputluoglu H, Dede DS, Gullu IH, Altundag K. Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. Breast 2007;16:111-112 (Pubitemid 46488817)
47. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-326
48. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109:497-499 (Pubitemid 46105944)
49. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, et al. A selective small molecule inhibitor of cMet kinase inhibits cMet-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-7355
50. Anfosso F, Bardin N, Vivier E, Sabatier F, Sampol J, Dignat-George F. Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J Biol Chem 2001;276:1564-1569 (Pubitemid 32096592)
51. Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003;102:184-191